ARQT vs LNC · rev $235.3M vs P/E 4.9, rev $9.85B
Arcutis Biotherapeutics Inc (ARQT) versus Lincoln National Corporation (LNC) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Lincoln National Corporation (LNC) is a insurance - life company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported LNC revenue for 2026-06-30 was $9.85B. Net income was $1.16B. Revenue was up 85.6% from 2026-03-31 to 2026-06-30. LNC currently screens at market cap $5.94B and trailing P/E 4.9.
ARQT currently screens at market cap $1.64B. LNC currently screens at market cap $5.94B and trailing P/E 4.9.
Not investment advice. Open the ARQT and LNC stock pages for the full models.
Not investment advice.